Release Date: Wednesday, December 2, 2020 Expiration Date: Thursday, December 2, 2021 |
EDUCATIONAL OVERVIEW The management of patients with pulmonary arterial hypertension (PAH) has undergone a vast transformation over the past decade with an improved understanding of the disease and an expansion of treatment options. Though patient survival was once considered the main treatment goal of PAH, outcomes can now include improved hemodynamics, prevention of clinical worsening, and improved quality of life. A key challenge in improving outcomes is early identification of the disease and initiating aggressive treatment. Greater emphasis is also being placed in identifying prognostic factors and assessing patient risk in order to tailor therapy accordingly. Treatment options for PAH are complex and dosing regimens must be specifically followed to avoid serious safety consequences. Research in the pathophysiology of PAH has revealed three major pathways involved in the disease process: the endothelin, nitric oxide, and prostacyclin pathways. Over the past two decades, several treatment options have become available that target these pathways that allow clinicians flexibility is designing optimal regimens. For patients with PAH, outcomes are often hindered by a delay in diagnosis and treatment. Primary care providers can play an important role in identifying the early signs of PAH and providing appropriate screening/diagnostic testing for early detection of disease. For patients being actively treated for PAH, PCPs must be aware of special considerations when managing coexisting or underlying conditions. This activity discusses the overall understanding of the disease pathophysiology and the medications used in the treatment of PAH.
|
TARGET AUDIENCE This continuing medical education activity meets the needs of primary care providers who can contribute to early detection of disease and who are responsible for the long-term management of patients with PAH. LEARNING OBJECTIVES Upon completing this activity, participants will be able to:
FACULTY
|
| ||||
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Center for Independent Healthcare Education (Center) and Vemco MedEd. Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Assistants
Nurse Practitioners For questions regarding the accreditation of this activity, please contact us at info@jointsponsor.com
Method of Participation and Instruction for Credit
Disclosure of Conflicts of Interest |
Fee Hardware/Software Requirements Software/Hardware Connection Speed System Check Copyright Statement Privacy Policy Joint Providership Commercial Support This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson. |
By clicking below, I acknowledge that I have read the entire CME information. |
|